PF-06482077
Author: Karolina Kujawa
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Pfizer’s PF-06482077 is a 20-valent pneumococcal conjugate vaccine, which is currently in Phase II development in the US and EU. PF-06482077 contains the 13 serotypes included in Prevnar 13 (4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A), as well as seven additional serotypes.
Analyst Outlook
The broad serotype coverage of PF-06482077 (20-valent pneumococcal conjugate vaccine; Pfizer) gives it significant market potential,
but it needs to demonstrate at least non-inferior immunogenicity to Prevnar 13 (13-valent pneumococcal conjugate vaccine; Pfizer) in
Phase II studies.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 PF-06482077 : Pneumococcal vaccines
LIST OF TABLES
5 Table 1: PF-06482077 drug profile
7 Table 2: Trials of PF-06482077 for pneumococcal vaccination
8 Table 3: PF-06482077 for pneumococcal vaccination – SWOT analysis
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Pneumovax 23 
Sign up to the